ArticleScientific reports2026
LSD1 promotes prostate cancer cell proliferation by upregulating PRAC1 expression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PRAC1, which is specifically expressed in prostate, rectal, and distal colon tissues, plays a critical role in the maintenance and self-renewal of prostate epithelial stem cells. However, the role of PRAC1 in prostate cancer is unclear. In this study, we found that PRAC1 expression is upregulated in prostate cancer cells and that PRAC1 knockdown represses the proliferation of prostate cancer cells. Moreover, lysine-specific demethylase 1 (LSD1) promoted prostate cancer cell proliferation by upregulating PRAC1 expression. TAK-418, an LSD1 inhibitor, suppressed prostate cancer cell proliferation by downregulating PRAC1 expression. Our results highlight PRAC1 or LSD1 inhibition as promising avenues for prostate cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.